The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
 
Jiayu Wang
No Relationships to Disclose
 
Yunjiang Liu
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Jifeng Feng
No Relationships to Disclose
 
Jianmin Fang
Employment - RemeGen; RemeGen (I)
Leadership - RemeGen
Stock and Other Ownership Interests - RemeGen
Research Funding - RemeGen
Patents, Royalties, Other Intellectual Property - RemeGen
 
Xuelian Chen
No Relationships to Disclose
 
Yiqun Han
No Relationships to Disclose
 
Qing Li
No Relationships to Disclose
 
Pin Zhang
No Relationships to Disclose
 
Peng Yuan
No Relationships to Disclose
 
Fei Ma
No Relationships to Disclose
 
Yang Luo
No Relationships to Disclose
 
Ying Fan
No Relationships to Disclose
 
Ruigang Cai
No Relationships to Disclose
 
Shanshan Chen
No Relationships to Disclose
 
Qiao Li
No Relationships to Disclose
 
Yiqun Li
No Relationships to Disclose
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)